Jump to main content
Jump to site search

Issue 75, 2014
Previous Article Next Article

Cyclometalated Ir(III) complexes as targeted theranostic anticancer therapeutics: combining HDAC inhibition with photodynamic therapy

Author affiliations

Abstract

The successful design and anticancer mechanistic studies of a series of cyclometalated Ir(III) complexes with histone deacetylase inhibitory and photodynamic therapy (PDT) activities are reported.

Graphical abstract: Cyclometalated Ir(iii) complexes as targeted theranostic anticancer therapeutics: combining HDAC inhibition with photodynamic therapy

Back to tab navigation

Supplementary files

Publication details

The article was received on 07 Jul 2014, accepted on 29 Jul 2014 and first published on 30 Jul 2014


Article type: Communication
DOI: 10.1039/C4CC05215C
Citation: Chem. Commun., 2014,50, 10945-10948
  •   Request permissions

    Cyclometalated Ir(III) complexes as targeted theranostic anticancer therapeutics: combining HDAC inhibition with photodynamic therapy

    R. Ye, C. Tan, L. He, M. Chen, L. Ji and Z. Mao, Chem. Commun., 2014, 50, 10945
    DOI: 10.1039/C4CC05215C

Search articles by author

Spotlight

Advertisements